New combo therapy targets Hard-to-Treat lymphoma

This study tests a combination of an immunotherapy drug (pembrolizumab) and low-dose radiation for people with non-Hodgkin lymphoma that has come back or not responded to prior treatments. Six participants will receive the drug plus radiation to one or more tumor sites. The goal is to see if this approach can shrink tumors and control the disease, but participants will continue immunotherapy long-term unless side effects or progression occur.